ClinicalTrials.gg
Not yet recruitingNCT07848880Updated Sep 30, 2026

A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease

A Phase 2 interventional study of DR10624 Injection and Placebo in Hypertriglyceridemia, sponsored by Zhejiang Doer Biologics Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Zhejiang Doer Biologics Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Hypertriglyceridemia with a site in China — 14 open to participants now, 19 under way, 5 of them phase 3. Hypertriglyceridemia · China.

Planned enrollment
10th of 25
315 · median 119
Started
2026
with 10 others
Phase 2
5 of 26
2 open now
Primary completion
2028-04
later than 12 of 18 live
Registered
26th of 26
by date
Lead sponsor
4 of 26
Zhejiang Doer Biologics Co., Ltd.

Among the 26 studies in Hypertriglyceridemia with a site in China, this one is the 10th largest by planned enrollment of the 25 interventional ones that give a count, is one of 11 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 12 of the 18 other live ones, and was the 26th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

14 of the 26 studies in Hypertriglyceridemia with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hypertriglyceridemia with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial in adults with moderate hypertriglyceridemia and diabetic kidney disease. Eligible participants complete a screening period and then randomized to four treatment groups: three active-dose groups of subcutaneous DR10624 and one placebo group. All groups receive weekly subcutaneous injections for a total of 64 weeks of double-blind treatment, followed by a 4-week post-treatment safety follow-up. The primary objective is to evaluate the triglyceride-lowering effect of DR10624 versus placebo. Secondary assessments include other lipid parameters, renal parameters, hepatic fat fraction, overall safety, and anti-drug antibody status.

03

Conditions studied

  • Hypertriglyceridemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants, aged 18 to 75 years at screening.
  2. 19.0-45.0 kg/m², body weight ≥50.0 kg.
  3. At least two triglyceride measurements of ≥2.3 mmol/L and \<5.7 mmol/L during the screening period, with an interval of more than 1 week between the two measurements.
  4. Diagnosis of type 2 diabetes mellitus for ≥12 weeks, with stable doses of glucose-lowering medication(s) for ≥8 weeks.
  5. Meets the diagnostic criteria for diabetic kidney disease as defined in relevant guidelines.
  6. and UACR meet the thresholds specified in the protocol.
  7. On stable doses of renoprotective medication for ≥4 weeks.
  8. Able to understand study procedures, maintain consistent lifestyle and follow all protocol-specified requirements, and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with non-diabetic kidney disease ,history of or planned kidney transplantation,solitary kidney ;or recent dialysis due to acute renal insufficiency.
  2. History of Class III-IV heart failure, obstructive valvular heart disease, or hypertrophic cardiomyopathy; uncontrolled hypertension or severe arrhythmia.
  3. Recent acute coronary syndrome or cardiac surgery,severe diabetic events or ocular complications or bone disorders.
  4. Unqualified laboratory results at screening: abnormal liver or pancreatic function indexes, elevated , elevated calcitonin, or positive // serology.
  5. Prior exposure to GLP-1R, GCGR, or FGF21R agonists; use of relevant drugs or participation in other interventional trials within 3 months; or use of DPP-4 inhibitors within 4 weeks.
  6. History of acute pancreatitis, chronic pancreatitis or symptomatic gallbladder disease.
  7. Severe psychiatric disorders, substance abuse, family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)or within the past 5 years.
  8. Lipid-lowering medications or medications that may exacerbate hypertriglyceridemia have not been at a stable dose for a sufficient duration.
  9. Pregnancy or lactation; refusal to use ; known to the study drug; or any condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
315 participants (estimated)

Study arms

  • Experimental
    Dose 1 DR10624 Group

    Subcutaneous injection of DR10624 once weekly

    Drug: DR10624 Injection

  • Experimental
    Dose 2 DR10624 Group

    Subcutaneous injection of DR10624 once weekly

    Drug: DR10624 Injection

  • Experimental
    Dose 3 DR10624 Group

    Subcutaneous injection of DR10624 once weekly

    Drug: DR10624 Injection

  • Placebo comparator
    Placebo Group

    Subcutaneous injection of placebo once weekly

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in fasting serum triglyceride concentration at Week 26

    Time frame: Baseline up to Week 26 of double-blind treatment period

Secondary outcomes

  1. Percentage change in fasting TG from baseline

    Percentage change in fasting TG from baseline

    Time frame: From first study drug injection through the end of treatment (up to 64 weeks)

  2. Percentage change in lipid profile from baseline

    The change from baseline in the following lipid parameters will be assessed: total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), small dense low-density lipoprotein cholesterol (sdLDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglyceride-rich lipoprotein cholesterol (TRL-C), and free fatty acids (FFA).

    Time frame: From first study drug injection through the end of treatment (up to 64 weeks)

  3. Change in urine albumin-to-creatinine ratio (UACR) from baseline

    Percentage change in urine albumin-to-creatinine ratio (UACR) from baseline

    Time frame: From first study drug injection through the end of treatment (up to 64 weeks)

  4. Change in eGFR from baseline

    The absolute change and percentage change in estimated glomerular filtration rate from baseline

    Time frame: From first study drug injection through the end of treatment (up to 64 weeks)

  5. Change in Liver Fat Content (LFC) Measured by MRI-PDFF

    The absolute change and percentage change in LFC from baseline measured by MRI-PDFF

    Time frame: From first study drug injection through the end of treatment (up to 64 weeks)

  6. Change in Liver Fat Content (LFC) Measured by MRI-PDFF

    The percentage of participants with ≥30% relative reduction in liver fat content (LFC) from baseline, ≥50% relative reduction in LFC from baseline, or absolute LFC \< 5%,

    Time frame: From baseline to Week 26

  7. Proportion of participants with treatment-emergent adverse events (TEAEs) throughout the study

    All adverse events emerging from the first study drug injection until 4 weeks after the last injection are captured, coded by MedDRA and graded per pre-defined severity criteria. The percentage of participants experiencing any TEAE and the distribution of maximum TEAE severity will be summarized for the full safety observation window.

    Time frame: First study drug injection through 4-week post-treatment safety follow-up

  8. Serum concentration of DR10624

    Pharmacokinetic assessment: serum DR10624 concentration at scheduled sampling time points

    Time frame: First study drug injection through 4-week post-treatment safety follow-up

  9. Positive rate of anti-drug antibody (ADA) against DR10624

    Positive rate of ADA against DR10624

    Time frame: First study drug injection through 4-week post-treatment safety follow-up

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.

Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2028
CompletionEst.
Mar 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07848880
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Yongliang Fang
Contact
yf@dorebio.com
+86 057128256206

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DR10624

Start the discussion